Journal article
Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis
DEA Greven, ES Cohen, DM Gerlag, J Campbell, J Woods, N Davis, A van Nieuwenhuijze, A Lewis, S Heasmen, M McCourt, D Corkill, A Dodd, J Elvin, G Statache, IP Wicks, IK Anderson, A Nash, MA Sleeman, PP Tak
Annals of the Rheumatic Diseases | Published : 2014
Abstract
Objective Previous work has suggested that the granulocyte macrophage colony stimulating factor (GM-CSF)-GM-CSF receptor a axis (GM-CSFRa) may provide a new therapeutic target for the treatment of rheumatoid arthritis (RA). Therefore, we investigated the cellular expression of GM-CSFRa in RA synovial tissue and investigated the effects of anti-GM-CSFRa antibody treatment in vitro and in vivo in a preclinical model of RA. Methods We compared GM-CSFRa expression on macrophages positive for CD68 or CD163 on synovial biopsy samples from patients with RA or psoriatic arthritis (PsA) to disease controls. In addition, we studied the effects of CAM-3003, an anti-GM-CSFR antibody in a collagen induce..
View full abstractGrants
Funding Acknowledgements
This work was partly funded by MedImmune; a wholly owned subsidiary of Astrazeneca. This work was also partly funded by CSL Ltd, Australia.